What’s new in ulcerative colitis?
31
Efficacy and safety of mirikizumab as maintenance therapy in patientswith moderately to severely active ulcerative colitis: results from the Phase 3 LUCENT-2 study
213
Efficacy and safety of upadacitinib maintenance therapy in patients with moderately to severely active ulcerative colitis: final results from the Phase 3 U-ACHIEVE maintenance study
373
Benefits of high versus low dose upadacitinib as maintenance treatment in ulcerative colitis patients who were responders to 8-week induction with upadacitinib: results from the U-ACHIEVE Phase 3 maintenance trial
546
Etrasimod 2MG once daily as treatment for moderately to severely active ulcerative colitis: results from the Phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials
732
Induction combination therapy with guselkumab and golimumab followed by guselkumab monotherapy maintenance: results of the Phase 2A, randomized,double-blind, proof-of-concept VEGA study
New therapies in Crohn’s disease
36
A cluster-randomised controlled trial of an enhanced treatment Algorithm for the management of Crohn's disease: REACT-2
173
52-weeks risankizumab subcutaneous maintenance dosing is efficacious and well tolerated in patients with moderate to severe Crohn's disease who had delayed response to 12-weeks IV risankizumab induction
306
Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn’s disease: results from the Phase 3 BERGAMOT study
464
Efficacy and safety of upadacitinib induction therapy in patients with moderately to severely active Crohn's disease: results from a randomized Phase 3 U-EXCEL study
581
Higher endoscopic and clinical remission rates with vedolizumab in early than in late Crohn’s disease: results from the LOVE-CD study (Low Countries Vedolizumab in CD Study)
Interviews
Assessing ulcerative colitis and evolving UC clinical remission goals
12
What are the key treatment goals for people with UC?
70
How can remission be defined, and what is your own preference when setting treatment goals?
132
What proportions of patients currently achieve clinical, endoscopic, or histologic remission?
197
Is there a place for symptomatic remission as a goal?
241
In the LUCENT-2 trial, was there sustained symptom control?
Advances and long term outcomes in Ulcerative Colitis
12
How common is bowel urgency for people with UC?
48
What impact does this have on patients’ lives?
103
Is this a symptom that can be controlled early?
134
Which agents offer the best efficacy for bowel urgency?
175
What are the most important long-term outcomes?
Ulcerative colitis treatments
12
How has the treatment landscape changed in UC in recent years?
72
What proportion of people do not respond to current agents?
153
Where should new agents such as those targeting IL-23 be positioned in the treatment algorithm?
222
What did we learn during the COVID-19 pandemic about patient preferences?
Upcoming next best therapeutic option for IBD
12
What are the most common complications in people with IBD, and how should they be handled?
55
Are there new agents on the horizon that could address some of these issues?
95
Are adult and paediatric complications the same, and what has adult data taught us about biological initiation in children?
158
What do you think will be the next big thing in IBD?
The LUCENT-1 induction trial
12
How easy is it to define symptom improvement and control in UC, and what are the symptoms that matter most to patients?
59
Typically, how well do patients respond to currently available treatments?
89
How does mirikizumab work, and what does it offer patients over current treatments?
128
What were the key findings in the LUCENT-1 induction phase?
Addressing fatigue in Crohn’s disease
12
How important are patient-reported outcomes in CD?
59
What is the significance of fatigue in CD, and should it be considered when making treatment choices?
100
Does improvement in fatigue correlate with clinical remission?
137
How do modern treatments such as mirikizumab perform for fatigue and other patient-reported outcomes?
